Estrella Immunopharma receives Nasdaq delisting notice for MVLS below $35M

Estrella Immunopharma, Inc.

Nasdaq letter Sept 1, 2026: MVLS below $35M for 30 straight business days (Jul 21-Aug 31, 2026).
Also fails alternative standards: stockholders' equity <$2.5M, net income <$500k.
Compliance period until Mar 1, 2027; must hit $35M MVLS for 10 consecutive days.
Common stock continues trading on Nasdaq Capital Market under ESLA; no immediate effect.
Company to monitor MVLS and evaluate options; no assurance of regaining compliance.

Featured in Daily 8-K Digest

Selected #4 for 2026-09-08. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.